.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE01_Saquinavir.Saquinavir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE01_Saquinavir.Saquinavir| name: | Saquinavir |
| ATC code: | J05AE01 | route: | oral |
| n-compartments | 2 |
Saquinavir is a protease inhibitor used as an antiretroviral agent in the treatment of HIV-1 infection. It was one of the first protease inhibitors approved for use but is now less commonly used due to newer agents with improved safety and efficacy. It is used in combination antiretroviral therapy for managing HIV/AIDS.
Pharmacokinetic parameters reported for HIV-infected adult patients, both male and female, under steady-state conditions receiving oral saquinavir-hardshell capsules 600 mg three times daily.
Dickinson, L, et al., & Aarons, LJ (2008). Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. The Journal of antimicrobial chemotherapy 62(6) 1344–1355. DOI:10.1093/jac/dkn399 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18824460
Acosta, EP, et al., & Mofenson, L (2001). Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV clinical trials 2(6) 460–465. DOI:10.1310/PUY3-5JWL-FX2B-98VU PUBMED:https://pubmed.ncbi.nlm.nih.gov/11742433
Dailly, E, et al., & Jolliet, P (2005). No significant influence of saquinavir hard-gel capsule administration on pharmacokinetics of lopinavir in combination with ritonavir: a population approach. Therapeutic drug monitoring 27(6) 782–784. DOI:10.1097/01.ftd.0000177663.89103.58 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16306855